312 related articles for article (PubMed ID: 11801571)
1. Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line.
Kohara H; Tabata M; Kiura K; Ueoka H; Kawata K; Chikamori M; Aoe K; Chikamori K; Matsushita A; Harada M
Clin Cancer Res; 2002 Jan; 8(1):287-92. PubMed ID: 11801571
[TBL] [Abstract][Full Text] [Related]
2. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells.
Fukuda M; Nishio K; Kanzawa F; Ogasawara H; Ishida T; Arioka H; Bojanowski K; Oka M; Saijo N
Cancer Res; 1996 Feb; 56(4):789-93. PubMed ID: 8631015
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a human small-cell lung cancer cell line resistant to a new water-soluble camptothecin derivative, DX-8951f.
Nomoto T; Nishio K; Ishida T; Mori M; Saijo N
Jpn J Cancer Res; 1998 Nov; 89(11):1179-86. PubMed ID: 9914787
[TBL] [Abstract][Full Text] [Related]
4. Establishment of a 7-ethyl-10-hydroxy-camptothecin-resistant small cell lung cancer cell line.
Chikamori M; Takigawa N; Kiura K; Tabata M; Shibayama T; Segawa Y; Ueoka H; Ohnoshi T; Tanimoto M
Anticancer Res; 2004; 24(6):3911-6. PubMed ID: 15736431
[TBL] [Abstract][Full Text] [Related]
5. The combination effect of amrubicin with cisplatin or irinotecan for small-cell lung cancer cells.
Takigawa N; Takeyama M; Shibayama T; Tada A; Kawata N; Okada C; Aoe K; Kozuki T; Hotta K; Tabata M; Kiura K; Ueoka H; Tanimoto M; Takahashi K
Oncol Rep; 2006 Apr; 15(4):837-42. PubMed ID: 16525668
[TBL] [Abstract][Full Text] [Related]
6. The role of topoisomerase I inhibitor in cisplatin-resistant ovarian cancer.
Minagawa Y; Kigawa J; Itamochi H; Terakawa N
Hum Cell; 2001 Sep; 14(3):237-43. PubMed ID: 11774743
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin down-regulates topoisomerase I activity in lung cancer cell lines.
Aoe K; Kiura K; Ueoka H; Tabata M; Chikamori M; Kohara H; Harada M; Tanimoto M
Anticancer Res; 2004; 24(6):3893-7. PubMed ID: 15736428
[TBL] [Abstract][Full Text] [Related]
8. In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction.
Kanzawa F; Koizumi F; Koh Y; Nakamura T; Tatsumi Y; Fukumoto H; Saijo N; Yoshioka T; Nishio K
Clin Cancer Res; 2001 Jan; 7(1):202-9. PubMed ID: 11205910
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin-resistant human small cell lung cancer cell line shows collateral sensitivity to vinca alkaloids.
Moritaka T; Kiura K; Ueoka H; Tabata M; Segawa Y; Shibayama T; Takigawa N; Ohnoshi T; Harada M
Anticancer Res; 1998; 18(2A):927-33. PubMed ID: 9615743
[TBL] [Abstract][Full Text] [Related]
10. Enhanced topoisomerase I activity and increased topoisomerase II alpha content in cisplatin-resistant cancer cell lines.
Minagawa Y; Kigawa J; Irie T; Kanamori Y; Itamochi H; Cheng X; Terakawa N
Jpn J Cancer Res; 1997 Dec; 88(12):1218-23. PubMed ID: 9473741
[TBL] [Abstract][Full Text] [Related]
11. MET increases the sensitivity of gefitinib-resistant cells to SN-38, an active metabolite of irinotecan, by up-regulating the topoisomerase I activity.
Sakai A; Kasahara K; Ohmori T; Kimura H; Sone T; Fujimura M; Nakao S
J Thorac Oncol; 2012 Sep; 7(9):1337-44. PubMed ID: 22722827
[TBL] [Abstract][Full Text] [Related]
12. Drug-induced down-regulation of topoisomerase I in human epidermoid cancer cells resistant to saintopin and camptothecins.
Taniguchi K; Kohno K; Kawanami K; Wada M; Kanematsu T; Kuwano M
Cancer Res; 1996 May; 56(10):2348-54. PubMed ID: 8625310
[TBL] [Abstract][Full Text] [Related]
13. A human small cell lung carcinoma cell line, resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide and cross-resistant to camptothecin with a high level of topoisomerase I.
Prost S; Riou G
Biochem Pharmacol; 1994 Aug; 48(5):975-84. PubMed ID: 8093110
[TBL] [Abstract][Full Text] [Related]
14. Combination effects of TAS-103, a novel dual topoisomerase I and II inhibitor, with other anticancer agents on human small cell lung cancer cells.
Sunami T; Nishio K; Kanzawa F; Fukuoka K; Kudoh S; Yoshikawa J; Saijo N
Cancer Chemother Pharmacol; 1999; 43(5):394-401. PubMed ID: 10100595
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of topoisomerase I catalytic activity as determinant of drug response in human cancer cell lines.
Voigt W; Vanhoefer U; Yin MB; Minderman H; Schmoll HJ; Rustum YM
Anticancer Res; 1997; 17(5A):3707-11. PubMed ID: 9413228
[TBL] [Abstract][Full Text] [Related]
16. Establishment of a CPT-11-resistant human ovarian cancer cell line.
Kijima T; Kubota N; Nishio K
Anticancer Res; 1994; 14(3A):799-803. PubMed ID: 8074481
[TBL] [Abstract][Full Text] [Related]
17. Additive effects of amrubicin with cisplatin on human lung cancer cell lines.
Yamauchi S; Kudoh S; Kimura T; Hirata K; Yoshikawa J
Osaka City Med J; 2002 Jun; 48(1):69-76. PubMed ID: 12375699
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary.
Itamochi H; Kigawa J; Sultana H; Iba T; Akeshima R; Kamazawa S; Kanamori Y; Terakawa N
Jpn J Cancer Res; 2002 Jun; 93(6):723-8. PubMed ID: 12079522
[TBL] [Abstract][Full Text] [Related]
19. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
Erlichman C; Boerner SA; Hallgren CG; Spieker R; Wang XY; James CD; Scheffer GL; Maliepaard M; Ross DD; Bible KC; Kaufmann SH
Cancer Res; 2001 Jan; 61(2):739-48. PubMed ID: 11212277
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic efficacy of a new topoisomerase I and II inhibitor TAS-103, against both P-glycoprotein-expressing and -nonexpressing drug-resistant human small-cell lung cancer.
Parajuli P; Yano S; Nishioka Y; Nokihara H; Hanibuchi M; Nishimura N; Utsugi T; Sone S
Oncol Res; 1999; 11(5):219-24. PubMed ID: 10608616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]